Contraste de los riesgos valorados para los tipos de tarjetas que han sido utilizadas como medio de pago en el sistema integrado de transporte público

Trabajo de InvestigaciónEl sistema integrado de transporte público SITP, es uno de los sistemas más grandes y sofisticados de transporte en Colombia; el ingreso a este se hace mediante tarjetas inteligentes sin contacto entre las cuales se encuentran: tarjeta monedero, cliente frecuente y tullave bajo la licitación de recaudo Bogotá. Debido a diferentes sucesos presentados, vulneración del medio de pago, se realizó una valoración de riesgos por medio de la norma ISO 27005,seguridad de la información de activos, basándose en la identificación de amenazas, vulnerabilidades y riesgos de las tarjetas utilizadas en el sistema.RESUMEN ABSTRACT INTRODUCCIÓN 1. GENERALIDADES 2. ESTABLECIMIENTO DEL CONTEXTO 3. IDENTIFICACIÓN DE RIESGOS 4. ESTIMACIÓN DE RIESGOS 5. EVALUACIÓN DE RIESGOS 6. CONCLUSIONES 7. RECOMENDACIONES Y TRABAJOS FUTUROS 8. ANEXOS 9. REFERENCIASPregradoIngeniero de Sistema

Revista Divulgación Científica Universidad del Rosario No. 6

Esta publicación tiene la decidida intención de acercar la investigación que realiza la Universidad del Rosario de Bogotá, Colombia, a un gran número de lectores para mostrarles, desde el periodismo científico, el quehacer investigativo de la institución.This publication has the determined intention of bringing the research carried out by the Universidad del Rosario in Bogotá, Colombia, to a large number of readers to show them, from scientific journalism, the investigative work of the institution

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols